Consider buying dips in HIMS (Hims & Hers Health) as it remains fundamentally undervalued with high-margin growth catalysts in GLP-1 weight loss drugs and upcoming peptide pipeline approvals through 2027.

META (Meta Platforms) presents an attractive long-term buying opportunity following a $17 billion legal settlement that eliminates a major risk overhang while market hesitation keeps the valuation subdued.

Prepare for short-term volatility in NVDA (NVIDIA) by using expected post-earnings dips as tactical entry points to capture its typical multi-day recovery pattern.

For NeoCloud computing exposure, look to establish positions in top-tier provider NBIS (Nebius Group) if price action pulls back into the $180–$190 range.

Alternatively, accumulate IREN (Iris Energy) as a deep-value AI cloud infrastructure play that trades 3.5x to 5x cheaper than peers and is uniquely positioned to price upcoming compute contracts at higher rates.

Hims & Hers Health, Inc. (HIMS)

• The speaker views HIMS as consistently undervalued, noting that it acts as a "punching bag" during broader risk-off sell-offs despite having strong underlying fundamentals.
• Two major growth catalysts are highlighted:
  • GLP-1 Weight Loss Drugs: The rollout is in full swing across their platform. Even on branded offerings, HIMS earns steady income through a $149/month doctor follow-up/prescription fee. Additionally, Eli Lilly's upcoming drug, Retatrutide, represents a significant potential pipeline addition.
  • Peptides: Potential approval across multiple peptide product rounds (timeline estimates range from November 2024 to January 2027), which the speaker believes the market is entirely overlooking.
• Key financial metrics highlighted:
  • Valuation ratio: Enterprise Value over Gross Profit/Revenue Growth is at 0.11.
  • Current EBITDA margin is 9%, with management targeting long-term EBITDA margins of 20% to 30% into the 2030s.
  • A Rule of 40 score of 46.

Takeaways

• Consider buying dips in HIMS as the current sell-off appears sentiment-driven rather than fundamental.
• Long-term investors can monitor progress in their GLP-1 expansion and pending peptide pipeline developments as key triggers for valuation upside.

NVIDIA Corporation (NVDA)

• NVDA has lagged the wider NASDAQ index over the past year (up 15% vs. the NASDAQ's 24%), despite strong revenue and product demand.
• The company announced a 17% price increase on AI servers, but the stock sold off on the news rather than rallying.
• The speaker anticipates short-term post-earnings downside driven by market maker sentiment and nitpicking, but notes that dips in NVDA often see a multi-day recovery pattern.
• High expectations mean a standard "good quarter" may not be enough to drive immediate upside in a cautious macro environment.

Takeaways

• Prepare for short-term post-earnings volatility, as high market expectations could cause an initial drop even on solid quarterly numbers.
• Watch for post-earnings pullbacks as potential entry opportunities if the stock follows its historical pattern of recovering shortly after an initial dump.

Meta Platforms, Inc. (META)

• Meta settled a major legal overhang for $17 billion, which the speaker considers a very bullish outcome given the original multi-trillion dollar concerns.
• The market’s muted reaction (up only 1% on the day after pre-market strength) reflects broader market risk aversion heading into NVDA earnings and upcoming Federal Reserve speeches at Jackson Hole.
• Strong financial fundamentals remain intact:
  • Annual revenue of approximately $228 billion.
  • Robust profitability with an 82% gross margin and a 48% EBITDA margin.

Takeaways

• The resolution of legal uncertainty removes a major overhang on META, making the subdued price action an attractive backdrop for long-term investors.
• Broad market fear, rather than company-specific weakness, appears to be holding back the share price.

Nebius Group (NBIS)

• Nebius is considered the higher-quality "NeoCloud" provider due to its specialized software stack, high-profile management, and a reported $2 billion direct investment relationship with NVIDIA.
• Nebius has targets to secure over 5 gigawatts of compute capacity for renting out GPU clusters.
• Potential risk factor: Because Nebius already has locked-in long-term customer contracts, rising hardware costs from NVIDIA's 17% server price hike may limit their ability to capture higher margins on existing commitments compared to uncontracted competitors.

Takeaways

• Maintain a long-term bullish stance on Nebius as an elite NeoCloud play, but monitor upcoming earnings and macro market pressures.
• A pullback into the $180–$190 price range would offer a more attractive risk-to-reward entry point.

IREN / Iris Energy (IREN)

• IREN represents the cheaper alternative in the NeoCloud space, trading at a valuation roughly 3.5x to 5x cheaper than Nebius on a trailing 12-month basis.
• Valuation metric stands around 0.09 on the speaker's growth ratio.
• Unlike Nebius, IREN has fewer pre-signed long-term deals, which positions them favorably to price upcoming compute contracts at higher rates following NVIDIA's price hikes.
• Like Nebius, IREN aims to reach 5+ gigawatts of compute capacity and maintains hardware supply agreements with NVIDIA.

Takeaways

• IREN offers deep value for investors looking for aggressive upside in AI cloud infrastructure at a fraction of the valuation of peers like Nebius.
• Investors should expect high volatility due to delayed analyst ratings and broader tech sector pullbacks heading into September.